Current national and international guidelines for T2D management recommend the use of GLP-1 RAs as a first- or second-line treatment (after metformin) due to their beneficial effects on body weight (BW) and cardiorenal risk [7,8]. Here, GCG is linked to type 2 diabetes mellitus.